ATLAS Biolabs is awarded Certified Service Provider Accreditation from Affymetrix for DMET analysis
Pharmacogenetic analysis of drug metabolism
(firmenpresse) - Berlin, September 25, 2012 - ATLAS Biolabs announces its accreditation as a certified Affymetrix DMET? Service Provider, offering the latest DMET? Plus Solution from Affymetrix. DMET Plus uses microarray testing to investigate common variations in genes encoding for drug-metabolism enzymes and drug transporters, and to identify their impact on the individual metabolic capacity. ATLAS Biolabs is the first European Certified Service Provider to offer the DMET technology for use in molecular pharmacogenetics in Germany.
Allelic variants with catalytic activities different from wild-type forms have been identified for an increasing number of drug-metabolizing enzymes and drug transporters. Analyzing the diversity of these proteins has become extremely important in the evaluation of drug toxicity. Thus, genotyping patients with respect to a particular genetic variant helps to avoid adverse drug responses, increase treatment efficacy, and achieve both improved healthcare outcomes and substantial economic benefits.
DMET Plus covers a broad range of 1,936 genetic variants across 231 relevant genes in one assay. Moreover, the test inspires high confidence in results and supports the rapid and comprehensive interpretation of genotyping data. DMET Plus will be useful in the discovery of novel biomarkers resulting from pharmacogenetic associations, as well as in the optimization of drug candidates. DMET could also improve translational and clinical trials by showing the effects of known metabolic pathways in poor drug responders, and confirm metabolic pathway involvement in newly discovered drug-metabolism associations.
"DMET helps translate pharmacogenetics into practice and will take us one step closer to the vision of personalized medicine," says Patrick Kelly, Director of Sales and Market Development at ATLAS Biolabs. "We are excited to offer our customers this new tool, which opens up the possibility of measuring existing and new metabolic pathways in a cost-effective and very reliable way."
The DMET? Plus Solution
DMET Plus from Affymetrix includes (a) a molecular inversion probe (MIP) panel to amplify the precise target DNA of interest; (b) an allele-specific oligonucleotide array providing a single-color readout on Affymetrix's GeneChip System® 3000 or the GeneChip® System 3000Dx v.2; and (c) the DMET analysis software, which offers both flexibility for user-defined reporting and the most comprehensive translation from genotypic data to star-allele classification and to predicted metabolizer status for the most clinically relevant genes. Assay performance is characterized by >99% average sample-call rates and >99.8% average sample reproducibility, which enables the accurate generation of haplotypes and supports longitudinal and other clinical research studies.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
About Affymetrix
Affymetrix technology is used by the world"s top pharmaceutical, diagnostic and biotechnology companies, as well as by leading academic, governmental, and non-profit research institutes. More than 25,000 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Santa Clara, Cleveland, Ohio, and Singapore. The company has about 900 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit http://www.affymetrix.com.
About ATLAS Biolabs GmbH
ATLAS Biolabs GmbH is a leading provider of complex analyses in molecular genetics, including microarray-based genomic services, targeted sequence capture, and next-generation sequencing in Europe. The company provides access to the DNA chip and sequencing platforms of all leading enterprises in this field (Affymetrix, Agilent, Illumina Life Technologies and Roche NimbleGen) and is a certified Affymetrix, Agilent and Roche NimbleGen service provider. Based in Germany, ATLAS Biolabs started its business operations in August 2007. Its production processes are subject to rigorous quality control at all stages according to the international standards of ISO 9001:2008 and ISO 13485:2003. Customers of ATLAS Biolabs include academic institutions, pharmaceutical and biotechnological enterprises, clinicians and registered physicians both in Germany and abroad. For more information, please go to www.atlas-biolabs.com.
Mugele Kommunikation
Dr. Mugele Katrin
Kurfürstenstr. 170
10785 Berlin
press(at)mugele-kommunikation.de
030/7816869
http://www.mugele-kommunikation.de
Datum: 25.09.2012 - 11:00 Uhr
Sprache: Deutsch
News-ID 186272
Anzahl Zeichen: 2931
contact information:
Contact person: Patrick Kelly
Town:
Berlin
Phone: +49 (0) 30/3 19 89 66-0
Kategorie:
Electronics & Semiconductors
Typ of Press Release:
Anmerkungen:
Diese Pressemitteilung wurde bisher 349 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ATLAS Biolabs is awarded Certified Service Provider Accreditation from Affymetrix for DMET analysis"
steht unter der journalistisch-redaktionellen Verantwortung von
ATLAS Biolabs GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
